The largest database of trusted experimental protocols

7 protocols using ponatinib

1

Tyrosine Kinase Inhibitor Dose Assessment

Check if the same lab product or an alternative is used in the 5 most similar protocols
Dasatinib (DASA), imatinib (IMA), nilotinib (NILO), and ponatinib (PONA) were purchased from Cayman Chemical Company (Ann Arbor, USA). After dissolving in DMSO, TKI were kept at – 20 °C until use. Stock concentrations were 20 mM for DASA, IMA and PONA, and 3 mM for NILO, respectively. Peak and IC50 concentrations were chosen according to the literature: DASA 150 nM (peak) and 10 nM (IC50); IMA 3000 nM (peak) and 600 nM (IC50); NILO 3000 nM (peak) and 30 nM (IC50); PONA 145 nM (peak) and 70 nM (IC50) (Peng et al. 2004 (link); Kantarjian et al. 2006 (link), 2010 (link); Rix et al. 2007 (link); Weisberg et al. 2007 (link); Cortes et al. 2012 (link); Menna et al. 2020 (link)). Direct effects of DMSO (maximum level was 0.1% v/v in NILO peak samples) were ruled out by including DMSO only as control throughout all experiments.
+ Open protocol
+ Expand
2

FGFR2 Inhibitor Dose-Response Assay

Check if the same lab product or an alternative is used in the 5 most similar protocols
NIH3T3 Empty, FGFR2–CLIP1, FGFR2–CLIP1 N549H cells were plated at a density of 10,000 cells per well in 96-well plates. Cells were treated for 72 h with either INCB054828 (Incyte), BGJ398 (Cayman Chemical), JNJ-42756493 (Cayman Chemical), AZD-4547 (Cayman Chemical), ponatinib (Cayman Chemical), or dovitinib (Cayman Chemical) ranging from 0.01 to 5000 nM. Quantification of viable cells was assessed using an MTS/PMS colorimetric assay. IC50 values were calculated in Prism (GraphPad) using a four-parameter dose–response model.
+ Open protocol
+ Expand
3

Evaluating FGFR Inhibitor Potency

Check if the same lab product or an alternative is used in the 5 most similar protocols
NIH3T3 cells were plated at 10,000 cells per well in 96-well plates in sextuplets. Cells were treated for 72 h with various selective and non-selective FGFR inhibitors ranging from0.01 to 5000 nM followed by quantification of viable cells using an MTS/PMS colorimetric assay. FGFR inhibitors tested include BGJ398, JNJ-42756493, AZD-4547, Ponatinib, Dovitinib, and TAS-120 (Cayman Chemical). The half maximal inhibitory concentration (IC50) of each FGFR inhibitor was calculated with GraphPad Prism using a four-parameter dose-response curve from four independent experiments.
+ Open protocol
+ Expand
4

Angiogenesis Inhibitors in Cell Culture

Check if the same lab product or an alternative is used in the 5 most similar protocols
Cell culture medium 199 (M199) was from Lonza (Verviers, Belgium). Recombinant human VEGF-165 was purchased from R&D Systems, Inc. (Minneapolis, MN, USA). Human plasma fibrinogen was acquired from Merck/Millipore (Darmstadt, Germany). Proteinase inhibitor mixture complete, EDTA-free, was purchased from Roche Diagnostics (Mannheim, Germany). Imatinib, nilotinib and ponatinib were from Cayman Chemical (Ann Arbor, MI, USA). All other reagents were from Sigma-Aldrich (Taufkirchen, Germany) unless otherwise stated.
+ Open protocol
+ Expand
5

Ponatinib Effects on HCAEC Cultures

Check if the same lab product or an alternative is used in the 5 most similar protocols
For our experiments, HCAEC line, cell culturing medium, trypsin-EDTA, Hank’s balanced salt solution (HBSS) and dimethyl-sulfoxide (DMSO) were obtained from Sigma-Aldrich (St. Louis, MO, USA). Plastic cell culturing flasks and plates were purchased from Greiner Bio-One (Nürtingen, Germany). Ponatinib was ordered from Cayman Chemical (Ann Arbor, MI, USA). HCAECs were cultured in MesoEndo growth medium in 75 cm2 flasks at 5% CO2 and 80% humidity. When the cells reached 80–90% confluence in the flask, they were plated in 6-well culture plates (105 cells/well), and after 2 days, the cells were treated for up to 48 h with clinically relevant and supratherapeutic concentrations of Ponatinib. The final concentrations of Ponatinib were 50, 150, and 1000 nM, DMSO (0.2 v/v %) was used as a negative control, and tumor necrosis factor alpha (TNF-α) (100 ng/mL; Gibco, Waltham, MA, USA) was used as a positive control. After the treatments, the cells were collected from both the plate and the culture medium.
+ Open protocol
+ Expand
6

Cell Culture and Drug Preparation

Check if the same lab product or an alternative is used in the 5 most similar protocols
All cell lines were purchased from DSMZ (Braunschweig, Germany) or ATCC (Manassas, VA, USA). The cell lines were regularly tested to exclude mycoplasma contamination and authenticated. All cell lines were grown at 37 °C and 5% CO2. A549 cells were cultured in DMEM medium (Gibco™, Thermo Fisher Scientific, Waltham, MA, USA). All other cell lines were cultured in RPMI 1640 medium (Gibco™, Thermo Fisher Scientific). Both media were supplemented with 10% fetal bovine serum (FBS), 10 U/mL penicillin, 10 µg/mL streptomycin and 2 mM L-glutamine (all Gibco™, Thermo Fisher Scientific). Bortezomib (S1013; Selleck Chemicals, Houston, TX, USA), cabozantinib (S1119; Selleck Chemicals), cytarabine (PHR1787; Millipore Sigma, Burlington, MA, USA), gilteritinib (HY-12432; MedChemExpress, Monmouth Junction, NJ, USA), ispinesib (HY-50759; MedChemExpress), midostaurin (M1323; Millipore Sigma), ponatinib (11494; Cayman Chemical, Ann Arbor, MI, USA), quizartinib (17986; Cayman Chemical), venetoclax (HY-15531; MedChemExpress) and WS6 (S7442; Selleck Chemicals) were dissolved in dimethyl sulfoxide (DMSO; Carl Roth, Karlsruhe, Germany) and diluted further in culture medium immediately before use.
+ Open protocol
+ Expand
7

FGFR Inhibitor Cytotoxicity Assay

Check if the same lab product or an alternative is used in the 5 most similar protocols
NIH3T3 and 293T cells were plated at 10,000 cells per well and MMNK-1 were plated at 5,000 cells per well in a 96-well plate and allowed to adhere for 24 hours. Cells were dosed with varying concentrations (0.01 to 5000 nM) of FGFR inhibitors and allowed to incubate for 72 hours. FGFR inhibitors tested included infigratinib, AZD4547 (22 (link)), erdafitinib, TAS120 (23 (link)), dovitinib, and ponatinib (Cayman Chemical). Quantification of viability was carried out with the CellTiter 96® Aqueous Non-Radioactive Cell Proliferation Assay (Promega) per manufacturer’s protocol. The half maximal inhibitory concentration (IC50) was calculated using GraphPad Prism. Four independent replicate experiments were conducted.
+ Open protocol
+ Expand

About PubCompare

Our mission is to provide scientists with the largest repository of trustworthy protocols and intelligent analytical tools, thereby offering them extensive information to design robust protocols aimed at minimizing the risk of failures.

We believe that the most crucial aspect is to grant scientists access to a wide range of reliable sources and new useful tools that surpass human capabilities.

However, we trust in allowing scientists to determine how to construct their own protocols based on this information, as they are the experts in their field.

Ready to get started?

Sign up for free.
Registration takes 20 seconds.
Available from any computer
No download required

Sign up now

Revolutionizing how scientists
search and build protocols!